GlassScriptPhysician profile
Lina Kay
NPI 1275696288
$3,304.92
in general payments reported to CMS, 2019-2025
37 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $441 · 2023: $1,210 · 2024: $1,243 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725 · Education: $23.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,725.00 |
| Education | $23.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.44 | 2021-2025 | Trulance, Xifaxan |
| Abbvie INC. | $403.53 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $259.44 | 2022-2025 | Entyvio, Trintellix |
| Gilead Sciences, INC. | $249.33 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $245.21 | 2022-2023 | Zeposia |
| Pfizer INC. | $162.45 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $134.93 | 2022-2024 | Linzess |
| Lilly USA, LLC | $116.28 | 2024 | Mounjaro, Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $99.78 | 2021-2025 | Dificid, Gardasil 9, Capvaxive |
| Ferring Pharmaceuticals INC. | $98.32 | 2022-2025 | Rebyota, Clenpiq, Adstiladrin |
| Nestle Healthcare Nutrition INC. | $82.44 | 2022-2023 | |
| Novo Nordisk INC | $80.11 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Genzyme Corporation | $74.12 | 2023-2024 | |
| Shield Therapeutics INC | $66.57 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $66.07 | 2023-2024 | Dupixent |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $62.18 | 2022-2023 | Zeposia |
| Aimmune Therapeutics, INC. | $61.10 | 2025 | Zenpep |
| Ardelyx, INC. | $59.43 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $51.52 | 2023-2024 | Voquezna |
| Alfasigma USA, INC. | $50.89 | 2021-2022 | |
| Exact Sciences Corporation | $43.40 | 2023-2025 | Cologuard Collection Kit |
| Nalu Medical, INC. | $41.37 | 2023-2024 | Nalu Neurostimulation System |
| Astrazeneca Pharmaceuticals LP | $37.22 | 2024 | Airsupra |
| Daiichi Sankyo INC. | $27.98 | 2023 | Injectafer |
| Axonics, INC. | $23.35 | 2024 | Axonics |
| Celltrion USA INC. | $23.11 | 2024 | Zymfentra |
| Intra-Sana Laboratories | $23.01 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Amgen INC. | $21.71 | 2024 | Repatha, Otezla |
| Saluda Medical Americas, INC. | $21.04 | 2024 | Evoke |
| Astellas Pharma US INC | $20.85 | 2024 | Veozah |
| Scynexis, INC. | $19.19 | 2022 | |
| Intercept Pharmaceuticals, INC. | $18.54 | 2023 | Ocaliva |
| Novartis Pharmaceuticals Corporation | $17.50 | 2025 | |
| Janssen Biotech, INC. | $15.83 | 2023 | Stelara |
| Idorsia Pharmaceuticals US INC | $15.31 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.78 | 2023 | Cyltezo |
| Currax Pharmaceuticals LLC | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lina Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.